spacer
home > ebr > spring 2002 > vaccination - who should we trust?
PUBLICATIONS
European Biopharmaceutical Review

Vaccination - Who Should We Trust?

Increasing numbers of concerned parents in the UK are rebelling against MMR as theonly 'safe' vaccination alternative for their children. According to the results of a recent Guardian/ICM opinion poll (1), some 75 per cent of parents interviewed would like the UK Government to provide free separate measles, mumps and rubella vaccinations for their children. The overall results of the poll suggest that all the recent efforts made by the Government have had little or no impact in reducing popular anxiety over this matter. Only 20 per cent of those included in the survey said they would "trust a lot" the advice given by politicians and their officials, with a worrying 30 per cent disregarding it altogether. So is this a new crisis of trust in the governing bodies or are we facing the same problems over and over again? With the number of measles cases rising not only in the UK but in other European countries such as Germany - in some incidents to the point of epidemic clusters - we should all be reminded of the potential horrors of the infections being prevented by mass vaccination: a wider incidence of diseases striking the population, in some cases with potentially fatal results.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Ian Gibson, Member of Parliament for Norwich North and Chair of the Commons Science and Technology Select Committee

Dr Ian Gibson was educated at Dumfries Academy and later attended Edinburgh University, where he was awarded a BSc and a PhD. He was a Royal Society Fellow at Edinburgh, and a Postdoctoral Fellow at Indiana University. Ian was also a visiting Professor at the University of Washington before joining the University of East Anglia (UEA) as a Lecturer in 1965. He was made a Senior Lecturer at UEA in 1970 and served as Dean of the School of Biological Sciences from 1991 to 1997. At UEA Ian was the head of a research team investigating various forms of cancer. In 1997 he was elected as Member of Parliament for Norwich North, a seat he kept after the 2001 election. In Parliament Ian specialised in science issues, particularly those relating to cancer research, founding the All Party Group on Cancer. During the last Parliament he was a member of the Commons Science and Technology select Committee, which he currently chairs, and was elected Chair of the Parliamentary Office of Science and Technology and the Parliamentary and Scientific Committee, a position he still holds.

spacer
Dr Ian Gibson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Senior Vice President Dr. David Daniel Honored in PharmaVOICE 100

Philadelphia, PA – August 1, 2019: Signant Health (formerly CRF Health and Bracket) today announces that its Senior Vice President, Dr. David Daniel, has been selected by PharmaVOICE as one of the top 100 most inspiring people within the life sciences sector. Dr. Daniel was selected from a large cross section of established professionals in the life sciences industry for his passion to continually improve the way in which science, technology and service interact. This honor swiftly follows another recent mark of distinction for Dr. Daniel, having been co-awarded the 2019 ISCDD Scientific Leadership Award.
More info >>

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement